BLUE to be added to the Nasdaq Biotechnology Index in the annual revamping.
ir.nasdaqomx.com
In total the following 21 securities will be added to the Index:
AcelRx Pharmaceuticals, Inc.(ACRX) , Agios Pharmaceuticals, Inc.(AGIO) , BioCryst Pharmaceuticals, Inc.(BCRX) , bluebird bio, Inc.(BLUE) , ChemoCentryx, Inc.(CCXI) , Cempra, Inc. , Chimerix, Inc. , Epizyme, Inc. , Esperion Therapeutics, Inc. , Horizon Pharma, Inc. , Cellular Dynamics International, Inc. , Insys Therapeutics, Inc. , KYTHERA Biopharmaceuticals, Inc. , OncoMed Pharmaceuticals, Inc. , Onconova Therapeutics, Inc. , Prothena Corporation plc , PTC Therapeutics, Inc. , Portola Pharmaceuticals, Inc. , Regulus Therapeutics Inc. , Sagent Pharmaceuticals, Inc. and Verastem, Inc. |
